Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Update on the management of vasoproliferative tumour
Journal Information
Vol. 93. Issue 7.
Pages 350-353 (July 2018)
Share
Share
Download PDF
More article options
Visits
6
Vol. 93. Issue 7.
Pages 350-353 (July 2018)
Short communication
Update on the management of vasoproliferative tumour
Actualización sobre el manejo del tumor vasoproliferativo
Visits
6
I. Temblador-Barba
Corresponding author
irenetemblador@gmail.com

Corresponding author.
, E.M. Delgado-Alonso, M. Toribio-García, L. Martínez-Campillo, I. Molina-Leyva, M. Martínez-Jiménez
Servicio de Oftalmología, Hospital Universitario Virgen de las Nieves, Complejo Hospitalario Universitario, Granada, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Abstract
Case report

Here we report a 19-year-old female patient who presented a vasoproliferative tumor. It caused complications, such as epiretinal membrane, macular edema, vitreous hemorrhage, and exudative retinal detachment. The patient was treated with 3 injections of intravitreal bevacizumab, an intravitreal dexamethasone implant, tocilizumab, and double freeze-thaw cryotherapy.

Discussion

Therapeutic options are: observation, if it is small, if it is a peripheral lesion, and if there seems to be no threat to vision. If it requires treatment, laser photocoagulation, intravitreal bevacizumab, trans-conjunctival cryotherapy, transpupillary thermotherapy, photodynamic therapy, brachytherapy plaques and surgery are the different options available. Recently, tocilizumab and intravitreal dexamethasone implants have been reported to be beneficial.

Keywords:
Vasoproliferative tumor
Intravitreal bevacizumab
Dexamethasone implant
Tocilizumab
Cryotherapy
Resumen
Caso clínico

Presentamos el caso de una paciente de 19 años con un tumor vasoproliferativo, en cuya evolución presentó una membrana epirretiniana, edema macular, hemovítreo y desprendimiento de retina exudativo. Se trató con 3 inyecciones intravítreas de bevacizumab, implante intravítreo de dexametasona, tocilizumab y 2 sesiones de crioterapia.

Discusión

Las opciones terapéuticas son: observación en los de menor tamaño, periféricos y sin amenaza para la visión. Si se necesita tratamiento, fotocoagulación con láser, crioterapia transconjuntival, inyecciones intravítreas de bevacizumab, termoterapia transpupilar, terapia fotodinámica, placas de radioterapia y cirugía son diferentes opciones disponibles. Recientemente se ha descrito que el tocilizumab y los implantes intravítreos de dexametasona pueden ser beneficiosos.

Palabras clave:
Tumor vasoproliferativo
Bevacizumab intravítreo
Implante de dexametasona
Tocilizumab
Crioterapia

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos